Last reviewed · How we verify

Bellus Health Inc. - a GSK company — Portfolio Competitive Intelligence Brief

Bellus Health Inc. - a GSK company pipeline: 0 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
3APS 3APS phase 3 P2X3 receptor antagonist P2X3 Respiratory
BLU-5937 BLU-5937 phase 3 P2X3 receptor antagonist P2X3 Pain Management / Neurology
Tramiprosate (3APS) Tramiprosate (3APS) phase 3 Amyloid-beta aggregation inhibitor Amyloid-beta (Aβ) Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Grünenthal GmbH · 1 shared drug class
  2. Mundipharma Research GmbH & Co KG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bellus Health Inc. - a GSK company:

Cite this brief

Drug Landscape (2026). Bellus Health Inc. - a GSK company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bellus-health-inc-a-gsk-company. Accessed 2026-05-17.

Related